Regulatory T cells suppress the expression of COX-2 in vulnerable plaque
- 19 Downloads
COX-2 contributes to local inflammation in atherosclerotic lesions. Regulatory T cells (Tregs) enhance the stability of atherosclerotic plaques. The aim of this study was to detect the potential relationship between Tregs and COX-2 in vulnerable plaques. Thirty ApoE −/− mice were fed a high-fat diet, and a silastic perivascular collar was placed around the right common carotid artery to induce vulnerable plaques. Eight weeks after collar placement, the mice were divided randomly into three groups: control, PBS, and Treg groups. Four weeks later, the right common carotid arteries were collected to detect the expression of COX-2. The results showed that Tregs significantly suppressed the expression of COX-2 in vulnerable plaques. In an in vitro experiment, RAW264.7 cells were divided randomly into three groups, which were precultured without T cells or with CD4 + CD25- T cells or Tregs for 48 h with an anti-CD3 antibody; then the cells were stimulated with LPS for 24 h. The RAW264.7 cells were harvested for RT-PCR and western blot assays and the results showed that Tregs downregulated COX-2 expression in RAW264.7 cells. Therefore, Tregs inhibited the expression of COX-2 in vulnerable plaques and macrophages, and COX-2 inhibition may be an important effect of Tregs that results in atherosclerotic plaque stabilization.
KeywordsAtherosclerosis Plaque instability Cyclooxygenase-2 Regulatory T cells
Sources of funding: this work was supported by the National 973 Basic Research Program of China (No. 2013CB530703 and No. 2015CB553604), the Program of Introducing Talents of Discipline to Universities (No. B07035), the State Key Program of National Natural Science of China (No. 61331001 and No.81530014), the International Collaboration and Exchange Program of China (No. 81320108004) and the Grants of the National Natural Science Foundation of China (No. 81425004, No. 81500340 and No. 81400195).
Compliance with ethical standards
Conflict of interest
All the authors declare no competing interests.
- 2.Yang T, Sun D, Huang YG, Smart A, Briggs JP, Schnermann JB (1999) Differential regulation of COX-2 expression in the kidney by lipopolysaccharide: role of CD14. Am J Physiol 277(1 Pt 2):F10–16Google Scholar
- 5.Kuge Y, Takai N, Ishino S, Temma T, Shiomi M, Saji H (2007) Distribution profiles of membrane Type-1 matrix metalloproteinase (MT1-MMP), matrix metalloproteinase-2 (MMP-2) and cyclooxygenase-2 (COX-2) in rabbit atherosclerosis: comparison with plaque instability analysis. Biol Pharm Bull 30(9):1634–1640CrossRefGoogle Scholar
- 10.Yand JM, Dong M, Meng X, Zhao YX, Yang XY, Liu XL, Hao PP, Li JJ, Wang XP, Zhang K, Gao F, Zhao XQ, Zhang MX, Zhang Y, Zhang C (2013) Angiotensin-(1–7) dose-dependently inhibits atherosclerotic lesion formation and enhances plaque stability by targeting vascular cells. Arterioscler Thromb Vasc Biol 33(8):1978–1985CrossRefGoogle Scholar
- 12.Kim CK, Cho DH, Lee KS, Lee DK, Park CW, Kim WG, Lee SJ, Ha KS, Goo Taeg O, Kwon YG, Kim YM (2012) Ginseng berry extract prevents atherogenesis via anti-inflammatory action by upregulating phase ii gene expression. Evid Based Complement Alternat Med 2012:490301Google Scholar
- 13.Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A (2001) Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104(8):921–927CrossRefGoogle Scholar
- 16.Browatzki M, Larsen D, Pfeiffer CA, Gehrke SG, Schmidt J, Kranzhofer A, Katus HA, Kranzhofer R (2005) Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-kappaB and activator protein 1 in a redox-sensitive manner. J Vasc Res 42:415–423CrossRefGoogle Scholar
- 17.Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J, APC, and PreSAP Trial Investigators (2006) Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114(10):1028–1035CrossRefGoogle Scholar